Consolidative therapy
Phase 3Small molecule
Consolidative therapy is one of 101 small molecule programs targeting Non-Small Cell Lung Cancer. It is currently in Phase 3.
3
Indications
5
Total Trials
5
Active Trials
100
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
414 competitors in Non-Small Cell Lung Cancer
#DrugCompanyPhaseTrials
1EMRELIS
AbbViePhase 3
SI-B001
SSichuan Baili Pharmaceutical Co., Ltd.
Phase 3
Divarasib
RochePhase 3
Consolidative therapy
SSun Yat-sen University
Phase 3
Remeron
OOrganon and Co
Preclinical
Vibramycin
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Treatment
GSKPreclinical
Aqupla
Jiangsu Simcere Pharmaceutical Co., Ltd.Preclinical
Ftorafur
TThe First Affiliated Hospital with Nanjing Medical University
Preclinical
PD-1 Inhibitors
BBioNTech US Inc.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Non-Small Cell Lung Cancer2 trials
Chemoradiotherapy1 trial
Hypofractionated Radiotherapy1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Consolidative therapy. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- SSun Yat-sen University